Eli Lilly and Company (LLY)vsPicard Medical, Inc. (PMI)
LLY
Eli Lilly and Company
$1,148.84
-0.53%
HEALTHCARE · Cap: $1.02T
PMI
Picard Medical, Inc.
$4.39
0.00%
HEALTHCARE · Cap: $12.37M
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 1320723% more annual revenue ($72.25B vs $5.47M). LLY leads profitability with a 35.0% profit margin vs 0.0%. LLY earns a higher WallStSmart Score of 76/100 (B+).
LLY
Strong Buy76
out of 100
Grade: B+
PMI
Avoid31
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 81 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
Revenue surging 85.5% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Expensive relative to growth rate
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 32.9x book value
0.0% earnings growth
Smaller company, higher risk/reward
ROE of 0.0% — below average capital efficiency
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bull Case : PMI
The strongest argument for PMI centers on Revenue Growth, Debt/Equity. Revenue growth of 85.5% demonstrates continued momentum.
Bear Case : LLY
The primary concerns for LLY are PEG Ratio, Debt/Equity, P/E Ratio. A P/E of 41.8x leaves little room for execution misses.
Bear Case : PMI
The primary concerns for PMI are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
LLY profiles as a growth stock while PMI is a hypergrowth play — different risk/reward profiles.
PMI is growing revenue faster at 85.5% — sustainability is the question.
LLY generates stronger free cash flow (3.0B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
LLY scores higher overall (76/100 vs 31/100), backed by strong 35.0% margins and 55.5% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Picard Medical, Inc.
HEALTHCARE · MEDICAL DEVICES · USA
Picard Medical, Inc., engages in the designing, manufacturing, production, supply, marketing, and sale of medical device products.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?